Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (42010121) | ||||||||||||
| Authors | Saifudeen M, Zhu S, Liang S, Eason M, Goupil A, Mische DF, Loch CM, Ma H, Chan M, Gujral TS | ||||||||||||
| Title | Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | Protein kinases are central to cell signaling and key drug targets in cancer. To inform potential repurposing of kinase inhibitors, we profiled 86 of the ~100 approved kinase inhibitors against 758 kinases, including 409 wild-type and 349 oncogenic variants using a biochemical kinase assay. Our results increase the number of druggable kinases from 89 to 235, revealing that 94% of mutations and 97% of fusions represented in our samples are inhibited by at least one existing drug. The dataset revealed mutation-specific selectivity, especially in tyrosine kinases FGFR and MET, highlighting gaps and repurposing opportunities. We experimentally validated several actionable findings, including tepotinib to target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway in pancreatic cancer and gilteritinib to overcome MET mutation-driven drug resistance and metastasis. To facilitate exploration of our data, we provide KIRHub, a web-based tool that allows identification of existing inhibitors of wild-type and mutated kinases to guide precision oncology. | ||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|---|---|---|---|---|
| FGFR2 | C491A | missense | unknown | FGFR2 C491A lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). C491A has been identified in the scientific literature (PMID: 25349422, PMID: 42010121), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Nov 2026). | |
| FGFR2 | C491S | missense | unknown | FGFR2 C491S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). C491A has been identified in the scientific literature (PMID: 41361008, PMID: 42010121, PMID: 37270847), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Nov 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 V555M | Advanced Solid Tumor | resistant | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3 V555M were resistant to Pemazyre (pemigatinib) in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Lytgobi (futibatinib) in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491S FGFR2 V564L | Advanced Solid Tumor | resistant | Selpercatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491S and FGFR2 V564L were resistant to Retevmo (selpercatinib) in culture (PMID: 42010121). | 42010121 |
| FGFR1 V561M | Advanced Solid Tumor | resistant | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561M were resistant to Balversa (erdafitinib) in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Truseltiq (infigratinib) in culture (PMID: 42010121). | 42010121 |
| FGFR3 V555M | Advanced Solid Tumor | resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3 V555M were resistant to Lytgobi (futibatinib) in culture (PMID: 42010121). | 42010121 |
| FGFR3 V555M | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3 V555M were resistant to Truseltiq (infigratinib) in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | resistant | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Pemazyre (pemigatinib) in culture (PMID: 42010121). | 42010121 |
| FGFR3 V555M | Advanced Solid Tumor | predicted - sensitive | Pralsetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gavreto (pralsetinib) inhibited viability in cells expressing FGFR3 V555M in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491S FGFR2 V564L | Advanced Solid Tumor | resistant | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491S and FGFR2 V564L were resistant to Pemazyre (pemigatinib) in culture (PMID: 42010121). | 42010121 |
| FGFR1 V561M | Advanced Solid Tumor | resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561M were resistant to Lytgobi (futibatinib) in culture (PMID: 42010121). | 42010121 |
| FGFR1 V561M | Advanced Solid Tumor | predicted - resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561M were resistant to Truseltiq (infigratinib) in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491S FGFR2 V564L | Advanced Solid Tumor | sensitive | Erdafitinib | Case Reports/Case Series | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited viability in cells expressing FGFR2 C491S and FGRF2 V564L in culture (PMID: 42010121). | 42010121 |
| FGFR1 V561M | Advanced Solid Tumor | predicted - sensitive | Pralsetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gavreto (pralsetinib) inhibited viability in cells expressing FGFR1 V561M in culture (PMID: 42010121). | 42010121 |
| FGFR3 V555M | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited viability in cells expressing FGFR3 V555M in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) decreased phosphorylation of Fgfr, Akt and S6rp, and inhibited viability in cells expressing FGFR2 C491A and FGFR2 V564L in culture (PMID: 42010121). | 42010121 |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | predicted - sensitive | Pralsetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gavreto (pralsetinib) decreased phosphorylation of Fgfr, Akt and S6rp, and inhibited viability in cells expressing FGFR2 C491A and FGFR2 V564L in culture (PMID: 42010121). | 42010121 |
| FGFR1 V561M | Advanced Solid Tumor | resistant | Selpercatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 V561M were resistant to Retevmo (selpercatinib) in culture (PMID: 42010121). | 42010121 |